Attovia Therapeutics has filed for a U.S. initial public offering (IPO) to raise capital for advancing its drug pipeline targeting immune-mediated diseases. Its lead candidate, ATTO-1310, has shown promising Phase 1 results with rapid relief for chronic itch conditions. The company is financially backed by top life science investors but will need significant further funding for later-stage development. IPO valuations for similar biopharma firms typically range between $250 million and $500 million, indicating market expectations for Attovia's potential growth.
Crédit Agricole Normandie-Seine reported strong first-half 2026 results with record credit and deposit volumes, a 15.2 million euro increase in net banking income, and a 13.9% rise in net profit to 65.1 million euros. The bank's credit portfolio reac...
Virtual Investor Conferences announced that presentations from the July 22-23 Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing for 90 days. Investors can access company materials and schedule one...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
Morgan Stanley has secured approval to list spot Ethereum (ETH) and Solana (SOL) exchange-traded funds (ETFs) on NYSE Arca, trading under the tickers MSSE and MSOL. These ETFs will stake a portion of their crypto holdings to generate additional rewar...
